Preventing Adverse Cardiac Events in COPD

PHASE3CompletedINTERVENTIONAL
Enrollment

280

Participants

Timeline

Start Date

June 30, 2020

Primary Completion Date

March 31, 2025

Study Completion Date

March 31, 2025

Conditions
Chronic Obstructive Pulmonary DiseaseCardiovascular Diseases
Interventions
DRUG

Bisoprolol

As in arm description

DRUG

Placebo Oral Tablet

As in arm description

Trial Locations (24)

2025

Middlemore Hospital, Auckland

2139

Concord Repatriation General Hospital, Sydney

2145

Westmead Hospital, Sydney

2170

Liverpool Hospital, Liverpool

2305

John Hunter Hospital & Hunter Medical Research Institute, Newcastle

2560

Campbelltown Hospital, Campbelltown

3240

Waikato Hospital, Hamilton

4032

Prince Charles Hospital, Brisbane

4102

Princess Alexandra Hospital, Brisbane

4215

Gold Coast University Hospital, Southport

6000

TrialsWest Pty Ltd, Perth

6009

Institute for Respiratory Health, Perth

6021

Medical Research Institute of New Zealand, Wellington

6150

Fiona Stanley Hospital, Murdoch

8011

University of Otago, Christchurch

9054

Dunedin Hospital, Dunedin

Unknown

Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences, Rohtak

St John's Medical College Hospital, Bangalore

Postgraduate Institute of Medical Education and Research, Chandigarh

All India Institute of Medical Sciences, New Delhi

Central Chest Clinic - Borella, Colombo

Central Chest Clinic, Colombo

Kandy National Hospital, Kandy

National Institute of Respiratory Diseases, Welisara

All Listed Sponsors
collaborator

National Health and Medical Research Council, Australia

OTHER

lead

The George Institute

OTHER

NCT03917914 - Preventing Adverse Cardiac Events in COPD | Biotech Hunter | Biotech Hunter